This is a supportive clinical publication but not a stock-moving catalyst. Monitor for any future FDA submissions or commercial partnership announcements related to the combination approach. The stock may see minimal reaction; no trading action warranted based on this release alone.
Price Chart
Executive Summary
Apyx Medical announced publication of a clinical study in Aesthetic Surgery Journal Open Forum showing that combining Avéli subcision with Renuvion helium plasma radiofrequency improved cellulite and skin laxity in 22 patients, with up to 81.8% showing improvement at 180 days and histological evidence of increased collagen and elastin. This adds to the evidence base for Renuvion in combination aesthetic treatments but does not represent a new FDA clearance, regulatory catalyst, or revenue event — it is a routine clinical publication with no immediate financial impact.
Key Facts
- Prospective study of 22 patients combining Avéli subcision with Renuvion for cellulite and skin laxity
- Up to 81.8% of patients showed improvement in cellulite appearance at 180 days
- Histological analysis in a subset showed increased collagen and elastin with improved dermal architecture
- Published in Aesthetic Surgery Journal Open Forum, a peer-reviewed journal
- No new FDA clearance, approval, or regulatory milestone announced
- No financial data, revenue impact, or guidance provided in the press release
Financial Impact
No financial impact — clinical publication only, no revenue or guidance disclosed
Risk Factors
- Clinical study is small (n=22) and investigator-initiated, not a company-sponsored pivotal trial
- No regulatory submission or expanded indication announced — commercial impact uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299245 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.41 | awaiting T+20 | — | $2.37 (−1.66%) |
Aug 7, 2026 11w ago | 8-K | $3.46 $3.05 | ▼ −11.85% | ▼ −10.94% | $2.37 (−31.50%) |
May 21, 2026 22w ago | 8-K | $4.13 $3.95 | ▼ −4.36% | ▼ −2.94% | $2.37 (−42.62%) |
May 21, 2026 22w ago | Press Release | $4.25 $4.04 | ▼ −4.94% | ▼ −5.27% | $2.37 (−44.24%) |
May 14, 2026 23w ago | 8-K | $4.36 $4.69 | ▲ +7.57% | ▲ +8.43% | $2.37 (−45.64%) |
May 11, 2026 24w ago | 8-K | $3.92 $4.86 | ▲ +23.98% | ▲ +24.28% | $2.37 (−39.54%) |
Apr 23, 2026 26w ago | Press Release | $3.80 $3.79 | ▼ −0.26% | ▼ −4.90% | $2.37 (−37.63%) |
Mar 10, 2026 32w ago | Press Release | $3.45 $3.81 | ▲ +10.43% | ▲ +10.59% | $2.37 (−31.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers